Evidence map›Paper›PMID 35717150›Full record

ArticleBMC cardiovascular disorders2022

MicroRNA expression profiles in familial hypertrophic cardiomyopathy with myosin-binding protein C3 (MYBPC3) gene mutations.

Li-Rong Lin, Xue-Qun Hu, Li-Hong Lu, Jia-Zhen Dai, Ning-Ning Lin, Re-Hua Wang, Zhang-Xin Xie, Xue-Mei Chen

Open access · goldAbstract read
In one paragraph

Article in BMC cardiovascular disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Molecular mechanisms and intervention approaches of heart failure (Review).International journal of molecular medicine · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Hypertrophic cardiomyopathy inThe journal of cardiovascular aging · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Li-Rong Lin *Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Xue-Qun Hu *Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Li-Hong LuShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China. lulihong168@163.com.
Jia-Zhen DaiShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Ning-Ning LinShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Re-Hua WangShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Zhang-Xin XieShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Xue-Mei ChenShengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Fujian Medical University · CNFujian Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial hypertrophic cardiomyopathy (FHCM) is an autosomal dominant inherited disease caused by mutations in genes encoding cardiac sarcomere proteins. MicroRNAs (miRNAs) play an important role in the pathogenesis of FHCM. In the present study, we aimed to determine the miRNA profile in FHCM patients with myosin-binding protein C3 (MYBPC3) gene mutations. We recruited three FHCM patients and age- and sex-matched controls. The three probands all had hypertrophic obstructive cardiomyopathy with severe myocardial hypertrophy, and two of the three had a history of sudden cardiac death, representing a "malignant" phenotype. We then compared the miRNA expression profiles of three FHCM patients carrying MYBPC3 gene mutations with those of the normal control group using miRNA sequencing technology. Differentially expressed miRNAs were verified using real-time polymerase chain reaction (qPCR). Target genes and signaling pathways of the identified differentially expressed miRNAs were predicted using bioinformatics analysis. A total of 33 significantly differentially expressed miRNAs were detected in the peripheral blood of the three probands, of which 28 were upregulated, including miR-208b-3p, and 5 were downregulated. Real-time PCR confirmed the upregulated expression of miR-208b-3p in FHCM patients (P < 0.05). Bioinformatics analysis showed that miR-208b-3p was mainly enriched in 79 target genes including UBE2V2, MED13, YBX1, CNKSR2, GATA4, andSOX5/6, et al. Gene ontology (GO) analysis of target genes showed that miR-208b was mainly involved in the processes of negative regulation of transcription from RNA polymerase II promoter, and regulation of transcription, DNA templated. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed that the target genes regulated by miR-208b-3p were mainly involved in the Wnt signaling pathway. These findings suggest that FHCM patients with MYBPC3 gene mutations have a specific miRNA expression profile, and that miR-208b-3p is significantly upregulated in cardiac hypertrophy. Our results also indicate that miRNA-208b-3p activates the Wnt signaling pathway through its target gene to promote cardiac hypertrophy.

Indexed as

Cardiomyopathy, Hypertrophic, FamilialMicroRNAsCardiomegalyCarrier ProteinsGene Expression ProfilingHumansMutationMyosin Binding Protein CMyosinsWnt Signaling PathwayCarrier ProteinsMicroRNAsMyosin Binding Protein CMyosinsFamilial hypertrophic cardiomyopathyGene mutationMicroRNA-sequencingMYBPC3

Identifiers

PMID35717150
PMCPMC9206743
OpenAlexW4283080297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.